Download PDF
Thromb Haemost 1997; 78(01): 145-150
DOI: 10.1055/s-0038-1657518
Molecular defects in rare bleeding disorders
Schattauer GmbH Stuttgart

Molecular Defects in Rare Bleeding Disorders: Hereditary Haemorrhagic Telangiectasia

Claire L Shovlin
Department of Genetics, Harvard Medical School, Boston, MA, USA; Royal Postgraduate Medical School, London, England, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Keywords

Postcapillary venule - vascular malformations - endoglin - ALKl - TGF-β - activin
 

  • References

  • 1 Rendu H. Épistaxis répetées chez un sujet porteur de petits angiomes cutanés et muquez. Gazette des Hopitaux (Paris) 1896; 135: 1322-1323
    PubMedGoogle Scholar
  • 2 Plauchu H, de Chadarévian JP, Bideau A, Robert J-M. Age-re lated profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297
    CrossrefPubMedGoogle Scholar
  • 3 Haitjema T, Westermann CJJ, Overtoom TTC, Timmer R, Disch F, Mauser H, Lammers J-WJ. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)-New insights in pathogenesis, complications, and treatment. Archives of Internal Medicine 1996; 156: 714-719
    CrossrefPubMedGoogle Scholar
  • 4 Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. New Engl J Med 1995; 333: 918-924
    CrossrefPubMedGoogle Scholar
  • 5 Shovlin CL, Winstock AR, Peters AM, Jackson JE, Hughes JMB. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. Quart J Med 1995; 88: 879-887
    PubMedGoogle Scholar
  • 6 Braverman IM, Keh-Yen A, Jacobson BS. Ultrastructure and threedimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990; 95: 422-427
    CrossrefPubMedGoogle Scholar
  • 7 Braverman IM, Keh-Yen A. Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 1983; 81: 489-497
    CrossrefPubMedGoogle Scholar
  • 8 Maire R, Schnewlin G, Bollinger A. Videomikroskopische Untersuchungen von Telangiektasien bei Morbus Osier und Sclerodermie. Schweiz. med Wschr 1986; 116: 335-338
    PubMedGoogle Scholar
  • 9 Shovlin CL, Scott J. Inherited diseases of the vasculature. Ann Rev Physiol 1996; 58: 483-507
    CrossrefPubMedGoogle Scholar
  • 10 Quick AJ. Telangiectasia: its relationship to the Minot-von Willebrand syndrome. Am J Med Sd 1967; 254: 585-601
    PubMedGoogle Scholar
  • 11 Conlon CL, Weinger RS, Cimo PL, Moake JL, Olson JD. Telangiectasia and von Willebrand’s disease in two families. Ann Int Med 1978; 89: 921-924
    CrossrefPubMedGoogle Scholar
  • 12 Hanna W, McCarioll D, Lin D, Chua W, McDonald TP, Chen J, Congdon C, Lange RD. A study of a Caucasian family with variant von Willebrand’s disease in association with vascular telangiectasia and haemoglobinopathy. Thromb Haemostas 1984; 51 (02) 275-278
    PubMedGoogle Scholar
  • 13 Larsson SO. Osier’s disease with impaired adhesion and aggregation of platelets. Acta Medica Scandinavica 1974; 196: 133-136
    PubMedGoogle Scholar
  • 14 Maggi CA, Ballarin E, Comin U, Mannucci PM. Hemorrhagic telangiectasia and hemophilia A: an occasional association?. Haematologica 1983; 68: 399-404
    PubMedGoogle Scholar
  • 15 Ferran M, Arderiu A, Vilardell M, Tornos J. Hereditary hemorrhagic telangiectasia and congenital factor XI deficiency. Medicina Clinica 1986; 86: 425-427
    PubMedGoogle Scholar
  • 16 Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107: 571-573
    CrossrefPubMedGoogle Scholar
  • 17 Saba HI, Morelli GA, Logrono LA. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. New Engl J Med 1994; 330: 1789-1790
    CrossrefPubMedGoogle Scholar
  • 18 Van Cutsem E. Oestrogen-progesterone, a new therapy of bleeding gastrointestinal vascular malformations. Acta Gastro-Enterologica Belgica 1993; 56: 02-10
    PubMedGoogle Scholar
  • 19 Akhurst RJ. The transforming growth factor β family in vertebrate embryogenesis. In: Growth factors and signal transduction in development. Nilsen-Hamilton M. ed Wiley-Liss, New York: 1994. pp 097-122
    Google Scholar
  • 20 Massague J. TGFb signaling: receptors, transducers and MAD proteins. Cell 1996; 85: 947-950
    CrossrefPubMedGoogle Scholar
  • 21 Marcias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87: 1215-1214
    CrossrefPubMedGoogle Scholar
  • 22 McDonald MT, Papenberg KA, Ghosh S, Glatfelder AA, Biesecker BB, Helmbold EA, Markel DS, Zolotor A, McKinnon WC, Vanderstoep JL, Jackson CE, Iannuzzi M, Collins FS, Boehnke M, Porteous ME, Guttmacher AE, Marchuk DA. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nature Gen 1994; 06: 197-204
    CrossrefPubMedGoogle Scholar
  • 23 Shovlin CL, Hughes JMB, Tuddenham EGD, Temperley I, Perembelon YFN, Scott J, Seidman CE, Seidman JG. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nature Gen 1994; 06: 205-209
    CrossrefPubMedGoogle Scholar
  • 24 Vincent P, Plauchu H, Hazan J, Fauré S, Weissenbach J, Godet J. A third locus for hereditary haemorrhagic telangiectasia maps to chromosome 12q. Hum Mol Genet 1995; 04: 945-949
    CrossrefPubMedGoogle Scholar
  • 25 Johnson DW, Berg JN, Gallione CJ, McAllister KA, Warner JP, Helmbold EA, Markel DS, Jackson CE, Porteous MEM, Marchuk DA. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Research 1995; 05: 21-28
    CrossrefPubMedGoogle Scholar
  • 26 Piantanida M, Buscarini E, Dellavecchia C, Minelli A, Rossi A, Buscarini L, Danesino C. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996; 33: 441-443
    CrossrefPubMedGoogle Scholar
  • 27 McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Gen 1994; 08: 345-351
    CrossrefPubMedGoogle Scholar
  • 28 Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marodel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous MEM, Marchuk DA. Mutations in the activin receptorlike kinase 1 gene in hereditary hemorrhagic telangiectasia type. Nature Gen 1996; 13: 189-195
    CrossrefPubMedGoogle Scholar
  • 29 McAllister KA, Baldwin MA, Thukkani AK, Gallione CJ, Berg JN, Porteous ME, Guttmacher AE, Marchuk DA. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type I suggest a dominant-negative effect of receptor function. Hum Mol Genet 1995; 04: 1983-1985
    CrossrefPubMedGoogle Scholar
  • 30 Shovlin CL, Hughes JMB, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Gen. 1997 in press.
    PubMedGoogle Scholar
  • 31 Muller J-Y, Michailov T, Izrael V, Bernard J. Maladie de Rendu-Osler dans une grande famille saharienne. La Nouvelle Presse Medicale 1978; 07: 1723-1725
    PubMedGoogle Scholar
  • 32 Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925-1933
    PubMedGoogle Scholar
  • 33 Westphal JR, Willems HW, Schalkwijk CJM, Ruiter DJ, deWaal RMW. A new 180-kDa dermal endothelial cell activation antigen: in vitroand in situcharacteristics. J Invest Dermatol 1993; 100: 27-34
    CrossrefPubMedGoogle Scholar
  • 34 Wang JM, Kumar S, van AgthovenAJ, Kumar P, Pye D, Hunter RD. Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 1995; 62: 791-796
    CrossrefPubMedGoogle Scholar
  • 35 Zhang H, Shaw ARE, Mak A, Letarte M. Endoglin is a component of the transforming growth factor (TGF)-β receptor complex of human pre-B leukemic cells. J Immunol 1996; 156: 565-573
    PubMedGoogle Scholar
  • 36 Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-19030
    PubMedGoogle Scholar
  • 37 Yamashita H, Ichijoro H, Grimsby S, Moren A, ten DijkeP, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β. J Biol Chem 1994; 269: 1995-2001
    PubMedGoogle Scholar
  • 38 Lastres P, Letamendia A, Zhang H, Ruis C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 133: 1109-1121
    CrossrefPubMedGoogle Scholar
  • 39 Hanks SK, Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995; 09: 576-596
    CrossrefPubMedGoogle Scholar
  • 40 Panchenko M, Mikhail P, Williams MC, Brody JS, Yu Q. Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels. Am J Physiol 1996; 270: L547-L558
    PubMedGoogle Scholar
  • 41 Attisano L, Wrana JL, Cheifetz S, Massague J. Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 1992; 68: 097-108
    CrossrefPubMedGoogle Scholar
  • 42 ten DijkeP, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin C-H. Characterization of type I receptors for transforming growth factor-β and activin. Science 1994; 264: 101-103
    CrossrefPubMedGoogle Scholar
  • 43 Berg JN, Guttmacher AE, Marchuk DA, Porteous MEM. Clinical heterogeneity In hereditary haemorrhagic telangiectasia are pulmonary arteriovenous malformations more common in families linked to endoglin?. J Med Genet 1996; 33 (03) 256-257
    CrossrefPubMedGoogle Scholar
  • 44 Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271-6274
    PubMedGoogle Scholar
  • 45 Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995; 55: 1452-1457
    PubMedGoogle Scholar
  • 46 Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995; 01: 74-79
    CrossrefPubMedGoogle Scholar
  • 47 Koh GY, Kim S-J, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995; 95: 114-121
    CrossrefPubMedGoogle Scholar
  • 48 Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis. Cell 1996; 87: 1153-1155
    CrossrefPubMedGoogle Scholar
  • 49 Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. J Clin Invest 1995; 95: 1363-1369
    CrossrefPubMedGoogle Scholar
  • 50 Clark ER, Clark EL. Microscopic observations on the extra-endothelial cells of living mammalian blood vessels. Am J Anat 1940; 66: 02-49
    PubMedGoogle Scholar
  • 51 Suri C, Jones PF, Patan S, Bartunkova S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-1180
    CrossrefPubMedGoogle Scholar
  • 52 Vikkula M, Boon LM, Cairaway III KL, Calvert JT, Diamond AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR. Vascular dysmoiphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181-1190
    CrossrefPubMedGoogle Scholar
  • 53 McCarthy SA, Bicknell R. Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 1993; 268: 23066-23071
    PubMedGoogle Scholar